Hematologic Malignancies Market Size & Forecast Report, 2014 - 2025

The global Hematologic Malignancies Market is predicted to reach USD 85.8 billion by 2025 depending on the growing prevalence of hematologic malignancies across the globe. Hematologic malignancies are also known as blood cancers that are found in bone marrow, blood, and lymph nodes. Hematologic malignancies are the fifth most commonly globally occurring cancer and are a major reason behind cancerous death in the United States. This cancer is projected to increase widely which also increases the need for its treatment. This will ultimately influence the hematologic malignancies industry in the forecast period.

Hematologic malignancies initiate in the bone marrow and consequently affect the production of blood and overall functionality. The stem cells present in the bone marrow support the development of RBC (red blood cells), WBC (white blood cells), and platelets. In cases of hematological malignancies, abnormal blood cells multiply abruptly resulting in various infections such as lymphoma, leukemia, and myeloma.

The classification of hematologic malignancies comprises leukemia (acute lymphocytic [ALL], acute myeloid [AML], chronic myeloid [CML], chronic lymphocytic [CLL]), myeloma, and lymphoma (Hodgkin’s and non-Hodgkin’s [NHL]). Disappointingly, neither there are any defined causes of hematological malignancies, nor there are any proven methods to avoid it. On the other hand, there are various risk factors associated with these types of cancers like sickness (fever), constant headaches, and fatigue.

The current generation lives a sedentary lifestyle which results in a large number of disorders. Such an unhealthy lifestyle is a major factor and is predicted to accelerate the growth of the hematologic malignancies market in the coming years. The increasing focus on research and development activities and modernizations in the healthcare field is estimated to boost the hematological malignancies market. Additionally, the increasing awareness among consumers regarding the availability of enhanced treatments is estimated to create promising growth opportunities for the market players in the future. Conversely, the inflated cost of branded drugs and lack of reimbursement policies are likely to obstruct the growth of the hematologic malignancies industry in the next few years. Also, the growing number of mergers & acquisitions are expected to fuel the growth of the market considerably in the forthcoming years.

The hematologic malignancies market is categorized on the grounds of disease condition, therapy, distribution channel, and geography. On the grounds of disease conditions, the market is divided into Leukemia, Lymphoma, and Myeloma. On the grounds of therapy, the hematologic malignancies industry is divided into Chemotherapy, Immunotherapy, and Targeted Therapy. Over the last few years, immunotherapy led the demand with a significant share in the entire market. This is due to the therapy being known to be most efficient and having the lowest risk of side effects. On the grounds of distribution channel, the hematologic malignancies market is divided into Hospital Pharmacies, Medical Stores, and E-commerce Platform.

Geographically, the hematologic malignancies industry is segmented as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to experience high growth in the forecast period owing to increasing patients of hematological cancers and the improved diagnostic techniques. The prominent market players profiled here include Bristol-Myers Squibb, AbbVie, Inc., Celgene Corporation, F. Hoffmann-La Roche Ltd., Novartis AG, and GlaxoSmithKline.

Market Segment:

Hematologic Malignancies Type Outlook (Revenue, USD billion, 2014 - 2025)
    • Leukemia
        • Acute Lymphocytic Leukemia
        • Chronic Lymphocytic Leukemia
        • Acute Myeloid Leukemia
        • Chronic Myeloid Leukemia
    • Lymphoma
    • Multiple Myeloma
    • Others

Hematologic Malignancies Therapy Outlook (Revenue, USD billion, 2014 - 2025)
    • Chemotherapy
    • Radiotherapy
    • Immunotherapy
    • Stem Cell Transplantation
    • Others

Hematologic Malignancies Regional Outlook (Revenue, USD billion, 2014 - 2025)
    • North America
        • the U.S.
        • Canada
    • Europe
        • Germany
        • the UK
    • the Asia Pacific
        • China
        • Japan
        • India
    • Latin America
        • Brazil
        • Mexico
    • Middle East & Africa
        • South Africa